| Bioactivity | DW-1350 is a LTB4 receptor antagonist. |
| Invitro | DW-1350 is a LTB4 receptor antagonist. DW-1350 shows inhibitory effects against osteoclast in terms of differentiation, formation, fusion and bone absorption[1]. |
| Name | DW-1350 |
| CAS | 491577-61-8 |
| Formula | C25H31N3O3S |
| Molar Mass | 453.60 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kang JH, et al. 5-Lipoxygenase inhibitors suppress RANKL-induced osteoclast formation via NFATc1expression. Bioorg Med Chem. 2015 Nov 1;23(21):7069-78. |